In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA, Big Pharma Act Quickly to Control Counterfeiting Upsurge

Executive Summary

Drug counterfeiting is on the rise--and drugs with inactive, incorrect, subpotent or superpotent ingredients are entering into the US drug supply at alarming rates. FDA commissioner Mark McClellan, MD, PhD has made it clear that identifying the best means to keep the drug supply safe is a fast-track effort at the agency. And this is not merely a top-priority regulatory effort--Big Pharma firms, fearful of safety problems--and, although they don't say so, lost sales--have lots of incentive to get involved in looking for solutions, too.
Advertisement

Related Content

Concerning Canada

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV002222

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel